SmithKline Beecham is acquiring the Sterling Winthrop R&D complex in Upper Providence Township, Pennsylvania USA, from Eastman Kodak for the sum of $120 million. The deal is expected to be completed in June this year.
The site covers around 150 acres and was originally developed to provide an integrated facility for all of the major discovery and development functions of Sterling Winthrop Pharmaceuticals, which was sold by Kodak to the French health and beauty company, Sanofi.
SB plans to relocate around 500 employees from leased facilities in West Conshohocken. In the long term, SB said it "expects to take advantage of this state-of-the-art facility to fulfil US R&D expansion needs."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze